Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche (RHHBY) 9M21 Sales Grow on Strong COVID-19 Tests, View Up
11:40am, Wednesday, 20'th Oct 2021
Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.
Roche reports higher sales and lifts full-year outlook
01:24am, Wednesday, 20'th Oct 2021
By Cecilia Butini
Roche raises 2021 outlook as COVID-19 tests continue powering sales
01:20am, Wednesday, 20'th Oct 2021
Roche raised its 2021 sales forecast on Wednesday after the Swiss drugmaker posted an 8% rise in nine-month revenues, powered by demand for COVID-19 tests and strength in the overall business helped b
Roche: One Of The Best Pharma Stocks You Can Buy
10:28pm, Monday, 18'th Oct 2021
Roche: One Of The Best Pharma Stocks You Can Buy
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting
12:12pm, Monday, 18'th Oct 2021
The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with the expression of the PD-L1 biomarker c
SANTA CLARA, Calif., Oct. 18, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with Ibex Medical Analytics, a global leader in artificial intel
Roche family shareholders will maintain stability - vice chairman
05:28am, Sunday, 17'th Oct 2021
The head of Roche's controlling group of shareholders is "very confident" stability can be maintained at the pharmaceuticals company after the next generation of heirs joined the family pool of invest
3 COVID-19 Pill Stocks to Watch
06:10am, Saturday, 16'th Oct 2021
These big drugmakers could soon compete against each other with oral COVID-19 therapies.
FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
12:30pm, Friday, 15'th Oct 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentr
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care
01:00am, Friday, 15'th Oct 2021
Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for patholo
Basel, 14 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new longer-term efficacy and safety data for ENSPRYNG® (satralizumab). The data show ENSPRYNG has a favourable benefit:ri
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new longer-term efficacy and safety data for Enspryng™ (satralizuma
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disa
Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status
10:58am, Tuesday, 12'th Oct 2021
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
Genentech's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer's Disease
04:48pm, Friday, 08'th Oct 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that gantenerumab, an anti-amyloid beta antibody developed for subcut
